M
Marc K. Hellerstein
Researcher at University of California, Berkeley
Publications - 327
Citations - 27366
Marc K. Hellerstein is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Lipogenesis & Adipose tissue. The author has an hindex of 82, co-authored 307 publications receiving 24589 citations. Previous affiliations of Marc K. Hellerstein include University of Minnesota & University of Washington.
Papers
More filters
Journal ArticleDOI
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
Kimber L. Stanhope,Jean-Marc Schwarz,Jean-Marc Schwarz,Nancy L. Keim,Steven C. Griffen,Andrew A. Bremer,James L. Graham,Bonnie Hatcher,Chad L. Cox,Artem Dyachenko,Wei Zhang,John P. McGahan,Anthony Seibert,Ronald M. Krauss,Sally Chiu,Ernst J. Schaefer,Masumi Ai,Seiko Otokozawa,Katsuyuki Nakajima,Katsuyuki Nakajima,Takamitsu Nakano,Carine Beysen,Marc K. Hellerstein,Lars Berglund,Peter J. Havel +24 more
TL;DR: The data suggest that dietary fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.
Journal ArticleDOI
Cholesterol Efflux and Atheroprotection Advancing the Concept of Reverse Cholesterol Transport
Robert S. Rosenson,H. Bryan Brewer,W. Sean Davidson,Zahi A. Fayad,Valentin Fuster,James A. Goldstein,Marc K. Hellerstein,Xian-Cheng Jiang,Michael C. Phillips,Daniel J. Rader,Alan T. Remaley,George H. Rothblat,Alan R. Tall,Laurent Yvan-Charvet +13 more
TL;DR: High-density lipoprotein has been proposed to have several antiatherosclerotic properties, including the ability to mediate macrophage cholesterol efflux, antioxidant capacity, antiinflammatory properties, nitric oxide–promoting activity, and ability to transport proteins with their own intrinsic biological activities.
Journal ArticleDOI
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A. Bluestone,Jane H. Buckner,Mark Fitch,Stephen E. Gitelman,Shipra Gupta,Marc K. Hellerstein,Kevan C. Herold,Angela P. Lares,Michael R. Lee,Kelvin W. Li,Weihong Liu,S. Alice Long,Lisa M. Masiello,Vinh Son Nguyen,Amy L. Putnam,Mary Rieck,Peter H. Sayre,Qizhi Tang +17 more
TL;DR: A phase 1 trial of adoptive Treg immunotherapy to repair or replace Tregs in type 1 diabetics was reported, and the therapy was safe, supporting efficacy testing in further trials and support the development of a phase 2 trial to test efficacy of the Treg therapy.
Journal ArticleDOI
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Steven G. Deeks,Terri Wrin,Teri Liegler,Rebecca Hoh,Matthew S. Hayden,Jason D. Barbour,Nicholas S. Hellmann,Christos J. Petropoulos,Joseph M. McCune,Marc K. Hellerstein,Robert M. Grant +10 more
TL;DR: Despite the presence of reduced drug susceptibility, antiretroviral- drug therapy can provide immunologic and virologic benefit and reflects continued antiviral-drug activity and the maintenance of a viral population with a reduced replicative capacity.
Journal ArticleDOI
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.
Bradley T. Messmer,Davorka Messmer,Steven L. Allen,Steven L. Allen,Jonathan E. Kolitz,Jonathan E. Kolitz,Prasad Kudalkar,Prasad Kudalkar,Denise Cesar,Elizabeth Murphy,Prasad Koduru,Prasad Koduru,Manlio Ferrarini,Simona Zupo,Giovanna Cutrona,Rajendra N. Damle,Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Kanti R. Rai,Kanti R. Rai,Marc K. Hellerstein,Marc K. Hellerstein,Nicholas Chiorazzi,Nicholas Chiorazzi +24 more
TL;DR: B-CLL is not a static disease that results simply from accumulation of long-lived lymphocytes, Rather, it is a dynamic process composed also of cells that proliferate and die, often at appreciable levels, the extent to which this turnover occurs has not been previously appreciated.